Home   >  
Apoptosis Pathway
PD 1/PD L1

Classified by application

All Products

Signaling Pathways

Research Areas

Nature products






Raw Materials

PD 1/PD L1

Chemical Structure Cat. No. Product Name CAS No.
Durvalumab Chemical Structure
BCP25841 Durvalumab 1428935-60-7
Durvalumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that blocks the interaction of programmed cell death ligand 1 (PD-L1) with the PD-1 and CD80 (B7.1) molecules.
AUNP-12 Chemical Structure
BCP25139 AUNP-12 1353563-85-5
AUNP-12 is an immune checkpoint modulator and also a PD-1 pathway inhibitor.
Avelumab Chemical Structure
BCP25212 Avelumab 1537032-82-8
Avelumab is a fully human IgG1 anti-PD-L1 monoclonal antibody with potential antibody-dependent cell-mediated cytotoxicity.
Atezolizumab Chemical Structure
BCP18055 Atezolizumab 1380723-44-3
Atezolizumab is a fully humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death-ligand 1 (PD-L1).
 PD-1-IN-1 Chemical Structure
BCP25947 PD-1-IN-1 1673534-76-3
Nivolumab Chemical Structure
BCP28580 Nivolumab 946414-94-4
Nivolumab, marketed as Opdivo, is a humanized IgG4 anti-PD-1 monoclonal antibody used to treat cancer.
PD1-PDL1 inhibitor 1 Chemical Structure
BCP15801 PD1-PDL1 inhibitor 1 1675201-83-8
PD1-PDL1 inhibitor 1 is an inhibitor of the PD-1 /PD-Ll protein/protein interaction, is an immunomodulator.
BMS-202 Chemical Structure
BCP16068 BMS-202 1675203-84-5
BMS-202 is an inhibitor of the PD-1/PD-L1 protein/protein interaction, mainly used for cancer treatment.
Pembrolizumab Chemical Structure
BCP24244 Pembrolizumab 1374853-91-4
Pembrolizumab (formerly MK-3475 and lambrolizumab) is a humanized antibody used in cancer immunotherapy. It is an IgG4 isotype antibody that blocks a protective mechanism of cancer cells, and allows the immune system to destroy those cancer cells. It targets the programmed cell death 1 (PD-1) receptor of lymphocytes.